You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞銀窩輪》連續兩日北水加持 藥明生物升穿30天線 瑞銀藥明認購 (11540)
阿思達克 10-17 09:04
受美股上週四奇蹟帶動,港股上週五枯木迎春,曾一度升逾600點,可惜實屬曇花一現,失守17000點關口,終收報17028點,只升198點。受大市帶動,藥明生物(02269)上週五領跑板塊,加上根據瑞銀港股通(滬)資金流顯示,連續兩日有資金流入藥明生物,曾一度升足一成半穿30天線,看好請留意瑞銀藥明認購 (11540),行使價60.05港元,23年2月到期,有效槓桿約4.2倍。而市場所見,也有一定資金流入熊證及認沽證,反映有部份投資者認為升幅已經到頂。如投資者看淡藥明,請留意瑞銀藥明認沽 (25311),行使價42.83港元,23年9月到期,有效槓桿約2倍。 美國9月核心CPI公布數據,連續第二個月增長,達8.2%並比市場預期高。或因此消息已在投資者意料之中,美股竟先跌後升,可惜期貨指數卻在上週五亞洲時段全面走跌,可見投資者對大環境不是很樂觀,如投資者希望兩手準備捕捉美股走勢,看好納指可留意納指認購(10629),行使價13100點,23年3月到期,有效槓桿約9.4倍。 如投資者看淡納指,可留意納指認沽(10447),行使價8800點,22年12月到期,有效槓桿約9.6倍。如投資者看好道指,可留意道指認購(10660),行使價31950點,23年3月到期,有效槓桿約9.7倍。如投資者看淡道指,可留意道指認沽(10497),行使價24400點,22年12月到期,有效槓桿約11倍。 更多窩輪牛熊資訊:瑞銀認股證牛熊證網站: http://www.ubs.com/hkwarrants 輪證教學及巿況焦點短片: https://www.youtube.com/channel/UCKw86qy4eBAInmd52MND45Q?view_as=subscriber 卓素華 瑞銀亞洲上市衍生產品銷售部主管 本產品並無抵押品。 如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。筆者為UBS AG的代表(作為證監會持牌人),並未持有相關上市公司的任何財務權益。本資料由瑞銀刊發,其並不構成買賣建議、邀請、要約或遊說。結構性產品價格可急升或急跌,投資者可能會蒙受全盤損失。過往表現並不反映將來表現。牛熊證備強制贖回機制而可能被提早終止,屆時 (i) N類牛熊證投資者將不獲發任何金額;而(ii) R類牛熊證之剩餘價值可能為零。投資前應瞭解有關風險,並諮詢專業顧問及查閱有關上市檔。UBS Securities Hong Kong Limited為結構性產品之流通量提供者,亦可能是唯一報價者或巿場參與者。(C) UBS 2022。版權所有。~ 重要聲明: 以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account